<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01946672</url>
  </required_header>
  <id_info>
    <org_study_id>P110903</org_study_id>
    <nct_id>NCT01946672</nct_id>
  </id_info>
  <brief_title>Lower-Limb Drainage Mapping in Pelvic Lymphadenectomy for Gynaecological Cancer</brief_title>
  <acronym>SENTIJAMBE</acronym>
  <official_title>Individualisation du Drainage Lymphatique Des Membres inférieurs Lors du Curage Pelvien Pour Cancer gynécologique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility of an isotopic technique to
      identify, and to map the lower-limb drainage nodes during pelvic lymphadenectomy for
      gynaecological cancers. The diagnostic value of our mapping method will be assessed, and we
      will determine the incidence of lymhedema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pelvic lymphadenectomy is associated with a significant risk of lower-limb lymphedema. In
      this study, we evaluate the feasibility of identifying the lower-limb drainage nodes (LLDNs)
      during pelvic lymphadenectomy for gynaecological cancers using an isotopic detection
      technique with a preoperative radiopharmaceutical injection into both feet Secondary
      objectives are to map lower-limb drainage, to assess the diagnostic value of our mapping
      technique, and to determine the incidence of lymphedema. LLDN mapping may allow the
      preservation of LLDNs, thereby decreasing the risk of lower-limb lymphedema and improving
      quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lower-limb drainage intraoperative isotopic detection rate in patients with pelvic lymphadenectomy for gynaecological cancers.</measure>
    <time_frame>day of surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomy of lower-limb drainage</measure>
    <time_frame>day of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with metastatic lower limb sampling</measure>
    <time_frame>2 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up of patients to identify complications, and namely lower-limb lymphedema.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Gynaecological Malignant Tumours With Indication of Pelvic Lymphadenectomy</condition>
  <arm_group>
    <arm_group_label>isotopic intraoperative detection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lower-limb drainage isotopic intraoperative detection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lower-limb drainage isotopic intraoperative detection</intervention_name>
    <description>A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.</description>
    <arm_group_label>isotopic intraoperative detection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients 18 years of age or older with indication of pelvic lymphadenectomy for
             gynaecological malignancy:

               -  High risk endometrial cancer (stage IB type I grade 3, stage I type II, stage&gt;
                  IB) or with metastatic sentinel lymph node,

               -  Early cervical cancer, or with metastatic sentinel lymph node,

               -  Ovarian cancer.

          -  Must provide her signed and informed consent

          -  Beneficiary of a health insurance

          -  Having received a medical examination

        Exclusion Criteria:

          -  Contraindication to pelvic lymphadenectomy

          -  Presence of lymphedema of the lower limbs

          -  Contraindication to radiomarkers (allergy or hypersensitivity to any component of the
             biomarker)

          -  Patient with dementia or altered mental status

          -  Pregnant or breast feeding patients

          -  Participation in any other clinical trial that could interfere with the study results
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Sophie BATS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>assistance publique des hopitaux de paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gynaecological malignancy</keyword>
  <keyword>pelvic lymphadenectomy</keyword>
  <keyword>lymphedema</keyword>
  <keyword>sentinel node</keyword>
  <keyword>reverse mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

